FDA Halts 23andMe Personal Genetic Tests
By Marcy Darnovsky; Jessica Cussins,
Medical Laboratory Observer
| 03. 10. 2014
Direct-to-consumer (DTC) genetic testing gained notoriety in the autumn of 2008. That was when two prestigious publications, The New Yorker and The New York Times, featured largely positive accounts of a celebrity “spit party”—at which notables dressed in cocktail attire ejected their saliva into test tubes for genetic analysis.1,2
That trendy gathering seemed to be the leading edge of a new era of personalized medicine. Companies selling saliva kits online promised that the tests would give customers medically crucial information about risks for a wide range of diseases. Some observers enthused that DTC gene tests would revolutionize medical care.
But at least to date, the reality has fallen far short of such claims.
One major setback for the DTC gene test industry came in 2010, when the Government Accountability Office (GAO) issued a stinging report3 after it had submitted identical DNA samples to four DTC gene testing companies and gotten back contradictory results. The GAO’s report called DTC gene tests “misleading and of little or no practical use.” The same year, when Pathway Genomics tried to sell a DTC...
Related Articles
By Holly Baxter, The Independent | 08.19.2025
In rural Pennsylvania, I’m hiking through the forest with Simone and Malcom Collins and discussing the executive order they wrote for Donald Trump. Just outside their house — beyond the chicken coop, where they gather their eggs for homemade cakes...
By Jacob Bogage, The Washington Post | 09.03.2025
The conservative group behind the Project 2025 governing playbook for President Donald Trump’s second term is set to propose sweeping revisions to U.S. economic policy meant to encourage married heterosexual couples to have more children.
The Heritage Foundation, a right-wing...
By Dennis Sponer, BioSpace | 09.03.2025
Imagine telling a child with sickle cell disease that a cure exists—but it’s too expensive for their insurer to cover. That’s not a hypothetical. It’s the reality of gene therapy today: a revolutionary medical breakthrough caught in the bottleneck of...
By Tia Ghose, Live Science | 09.16.2025
Twenty-six years ago today, on Sept. 17, a teenager who had received an experimental gene therapy died. His death led to needed changes in the clinical trial process while also spurring skepticism that would ultimately stall the field of gene...